A Study of Mezagitamab in People With Immune Thrombocytopenia

Full Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Avi Leader’s office at 646-608-4340.

Protocol
26-336
Phase
Phase III (phase 3)
Investigator
Avi Leader
Co-Investigators
Jeffrey Zwicker
Diseases
Hematology
Hematology › Hematologic Disorders
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06722235
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description